First-line chemotherapy for advanced ovarian cancer: Paclitaxel, cisplatin and the evidence

British Journal of Cancer

Volumn 78, Issue 11, 1998, Pages 1471-1478

  Sandercock, J ^a   Parmar, M K B ^a   Torri, V ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cisplatin; Ovarian cancer; Paclitaxel; Randomized trials

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031795302     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.709     Document Type: Article

References (33)

1. A'Hern RP and Gore ME (1995) Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 45: 726-732
2. Calvert AH, Newell DR, Gumbrell LA. O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E (1989) Carboplatin dosage: prospective cvaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
3. Colombo N, Pittelli MR, Parma G, Marzola M, Torri V and Mangioni C (1993) Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose vs dose-intense cisplatin chemotherapy. Proc Am Soc Clin Oncol 15: abstract 806
4. Colombo N, Marzola M, Parma G, Cantù MG, Tarantino G, Fornara G and Gueli-Alletti D (1996) Paclitaxel vs CAP (cyclophosphamide, adriamycin, cisplatin) in recurrent platinum-sensitive ovarian cancer: a randomized phase III study. Proc Am Soc Clin Oncol 15: abstract 751
5. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S and Rubagotti A (1996) High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14: 351-356
6. du Bois A, Nitz U, Schröder W, Schiller S, Jackisch C, Lück HJ, Meier W and Möbus V for the AGO Study Group (1997) Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: interim analysis of an AGO Study Group trial. Proc Am Soc Clin Oncol 16: abstract 1272
7. du Bois A, Richter B, Warm M, Costa S, Bauknecht T, Lück HJ, Meier W and Möbus V for the AGO Study Group (1998) Cisplatin/paclitaxel vs carboplatin/paclitaxel as first-line treatment in ovarian cancer. Proc Am Soc Clin Oncol 17: abstract 1395
8. Fanning J, Bennett TZ and Hilgers RD (1992) Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80: 954-960
9. Gore M, A'Hern R and Swenerton K (1997) Good manners for the pharmaceutical industry. Lancet 350: 370
10. ICON Collaborators (1998) ICON2: a randomised trial of single agent carboplatin against the 3-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet (in press)
11. Jakobson A, Bertelsen K, Andersen JF, Havsteen H, Jakobson P, Moeller KA, Nielsen K, Sandberg E and Stroeyer I (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15: 193-198
12. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruiekshank DJ, Alkinson RJ, Soukop M, Rankin EM, Cassidy J, Davis JA, Reed NS, Crawford SM, MacLean A, Swapp GA, Sarkar IK, Kennedy JH and Symonds RP (1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329-333
13. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J and Symonds RP for the Scottish Gynaecology Cancer Trials Group (1996) Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14: 2113-2119
14. Kirkwood JM, Lotze MT and Yasko JM (1994) Current Cancer Therapeutics, pp. 1-3 Princeton Academic Press: Philadelphia
15. Lacave AJ, Peláez I and Palacio I (1996) Chemotherapy for ovarian cancer. N Engl J Med 334: 1269-1270
16. Levin L and Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756-767
17. Levin L, Simon R and Hryniuk W (1987) Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 85: 1732-1742
18. Markman M, Bundy B, Benda J, Alberts D, Wadler S, Fowler J, Clarke-Pearson D and Carson LF for the Gynecologic Oncology Group (1998) Randomized phase III study of intravenous cisplatin/paclitaxel versus moderately high dose intravenous carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer. Proc Am Soc Clin Oncol 17: abstract 1392
19. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE and Davidson M (1993) A phase III trial comparing cisplatin/cytoxan and cisplatin/paclitaxel in advanced ovarian cancer. Proc Am Soc Clin Oncol 12: abstract 808
20. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY and Davidson M (1995a) Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol 14: abstract 771
21. McGuire WP, Hoskins J, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS and Woodward J (1995b) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589-1599
22. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson MD (1996) Cyclophosphamide and cisplatin compared vuth paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
23. Muggia FM, Braly PS, Brady MF, Sutton G, Copeland LJ, Lentz SL, Alvarez RD, Kucera PR and Small J for the Gynecologic Oncology Group (1997) Phase III of cisplatin or paclitaxel versus their combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group (GOG) study. Proc Am Sod Clin Oncol 16: abstract 1257
24. Muggia FM, Braly PS, Brady MF, Sutton G, Copeland LJ, Alvarez RD, Kucera PR and Small J (1998) Phase III comparison of single agents, cisplatin or paclitaxel, versus their combination in suboptimal stage III and IV epithelial ovarian cancer: a Gynecologic Oncology Group study. (submitted)
25. Neijt JP, Hansen M, Hansen SW, Sørensen PG, Sessa C, Witteveen PO, Engelholm SA, Stigaard L, Roer O and Lund B (1997) Randomised phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 16: abstract 1259
26. Ovarian Cancer Meta-analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9: 1668-1674
27. Parmar MKB and Sandercock J (1996) Chemotherapy for ovarian cancer. N Engl J Med 334: 1268-1269
28. Parmar MKB, Stewart LA and Altman DG (1996) Meta-analysis of randomised trials: when the whole is more than just the sum of the parts. Br J Cancer 74: 496-501
29. Parmar MKB, Torri V and Stewart LA (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (in press)
30. Piccart M, Bertelsen K, Stuart G, James K, Cassidy J, Kaye S, Hoctin Boes G, Timmers P, Roy JA and Pecorelli S (1997) Is cisplatin-paclitaxel the standard first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 16: abstract 1258
31. Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J, Kaye S, Timmers P, Roy JA and Piccart MJ (1998) Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol 17: abstract 1394
32. Torri V, Korn EL and Simon R (1993) Dose intensity analysis in advanced ovarian cancer patients. Br J Cancer 67: 190-197
33. Torri V on behalf of the International Collaborative Ovarian Neoplasm Studies (1996) Randomised study of cyclophosphamide, doxorubicin and cisplatin vs single agent carhoplatin in ovarian cancer patients requiring chemotherapy: interim results of ICON2. Proc Am Soc Clin Oncol 15: abstract 752